Brentuximab Vedotin in Heavily Pretreated Patients with Refractory Hodgkin's Lymphoma
N Mikhailova, E Borzenkova, M Ivanova, I Moiseev, E Kondakova, I Kazantsev, A Alyansky, B Afanasyev · Klinische Pädiatrie · 2014 · Heft 03
Bibliografische Angaben
Zusammenfassung
The goal: To estimate the efficacy and safety of brentuximab vedotin in heavily pretreated adolescent and young adults patients with refractory Hodgkin's lymphoma. Patients and methods: 21 patients with median age 24 (range 14 – 41) were treated by 6 cycles (range 2 – 16) of brentuximab vedotin. The median number of previous lines of treatment was 5.4 (range 2 – 10). 66.6% of patients underwent autologous HSCT and 2 patients were treated with allogeneic HSCT before first dose of brentuximab. 76% of patients had primary refractory disease, 100% had chemoresistant relapses. 19 patients had progressive disease befo…
